Sumitomo Pharma Co., Ltd.

SMDPY · OTC
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Assets
Cash & Equivalents$260,622$20,453,000$23,116,000$85,393,000
Short-Term Investments$0$0$16,840,000$0
Receivables$861,719$83,380,000$74,840,000$94,323,000
Inventory$560,348$89,751,000$94,222,000$107,426,000
Other Curr. Assets$153,028$63,134,000$44,150,000$46,546,000
Total Curr. Assets$1,835,718$256,718,000$253,168,000$333,688,000
Property Plant & Equip (Net)$304,290$46,103,000$46,648,000$52,613,000
Goodwill$1,330,243$191,175,000$197,406,000$208,787,000
Intangibles$1,127,467$164,726,000$172,509,000$194,484,000
Long-Term Investments$561,222$7,346,000$72,339,000$0
Tax Assets$3,142$0$534,000$0
Other NC Assets$108,623$67,265,000$0$62,543,000
Total NC Assets$3,434,987$476,615,000$489,436,000$518,427,000
Other Assets$0$0$0$0
Total Assets$5,270,705$733,333,000$742,604,000$852,115,000
Liabilities
Payables$284,701$39,308,000$38,544,000$49,278,000
Short-Term Debt$27,085$50,188,000$46,440,000$254,960,000
Tax Payable$0$0$1,577,000$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$1,035,874$142,191,000$154,042,000$195,101,000
Total Curr. Liab.$1,347,659$231,687,000$240,603,000$499,339,000
LT Debt$1,752,717$259,057,000$258,982,000$119,463,000
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$96,144$0$26,550,000$0
Other NC Liab.$275,844$66,356,000$46,990,000$67,198,000
Total NC Liab.$2,124,705$325,413,000$332,522,000$186,661,000
Other Liabilities$0$0$0$0
Cap. Leases$0$0$0$0
Total Liabilities$3,472,363$557,100,000$573,125,000$686,000,000
Equity
Pref Stock$0$0$0$0
Common Stock$151,674$22,400,000$22,400,000$22,400,000
Retained Earnings$998,856$57,924,000$46,784,000$41,601,000
AOCI$652,429$96,591,000$100,977,000$102,796,000
Other Equity-$4,618-$682,000-$682,000-$682,000
Total Equity$1,798,341$176,233,000$169,479,000$166,115,000
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$5,270,705$733,333,000$742,604,000$852,115,000
Net Debt$1,519,179$288,792,000$282,306,000$289,030,000
Sumitomo Pharma Co., Ltd. (SMDPY) Financial Statements & Key Stats | AlphaPilot